NSN 6505-01-618-5356 · NIIN 016185356 · FSC 6505
NO DASHES 6505016185356
In Stock
EMTRICITABINE AND TENOFOVIR TABL
Drugs and Biologicals
Technical characteristics
3 rows
Straight from the federal item record. Entries the record leaves empty are shown empty — nothing is filled in on its behalf.
| MRC | Requirement | Value |
|---|---|---|
| CXCY | PART NAME ASSIGNED BY CONTROLLING AGENCY | EMTRICITABINE/TENFOVIR (200MG/300MG) TABS 30S |
| AJCN | PROTECTIVE STORAGE FEATURE | CONTROLLED ROOM TEMPERATURE |
| FEAT | SPECIAL FEATURES | 200MG EMTRICITABINE AND 300MG OF TENOFOVIR DISOPROXIL FUMARATE; 30 TABLETS PER BOTTLE; TAKEN ORALLY; COMBINATION OF EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE IS INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS (SUCH AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS OR PROTEASE INHIBITORS) FOR THE TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER; ALSO APPROVED FOR USE IN COMBINATION WITH SAFER SEX PRACTICES FOR PRE-EXPOSURE PROPHYLAXIS (PREP), TO REDUCE THE RISK OF SEXUALLY ACQUIRED HIV-1 INFECTION IN ADULTS AT HIGH RISK |